First quarter 2024 results
First quarter 2024 results were reviewed by management during a conference call with the financial community on April 25th. The presentation was followed by a Q&A session.
14:30 - 16:00 CET (8:30am – 10am EST)
Featuring
Paul Hudson
Chief Executive Officer
François-Xavier Roger
Chief Financial Officer
Houman Ashrafian
R&D
Highlights
Paul Hudson comments on Q1 2024 results
We are off to an excellent start in 2024, delivering on our strategic priorities and a transformation of our portfolio of medicines and vaccines to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth.
Paul Hudson
Chief Executive Officer